A filed application answers a legal question and leaves the commercial one untouched. Somebody still has to make the thing, put it in a box, get it onto a shelf and persuade a stranger to pay for it. For an independent inventor there are only three ways that happens, and the choice between them shapes every decision that follows — how much capital is needed, how long the wait is, and how much of the eventual revenue ever arrives.
Route One
Licensing: Renting the Right to Somebody Already Doing It
A licence transfers the right to make and sell in exchange for a royalty, usually a percentage of net sales. The licensor keeps ownership of the patent; the licensee takes on tooling, manufacturing, distribution, marketing and inventory risk. For an inventor without a factory or a sales operation, this is the ordinary route, and the reason is simple: a company already selling into the category has the shelf space, the buyers' phone numbers and the production line. Reaching a market it takes them nine months to reach would take an individual a decade.
Royalty rates in consumer goods commonly sit between two and six per cent of net sales — sometimes lower in commodity categories, higher where the patent is genuinely blocking. New inventors tend to fixate on this percentage. It is usually the least negotiable and least important term in the agreement.
The Terms
What Actually Decides Whether a Licence Pays
Four clauses do more work than the rate. Exclusivity: an exclusive licence hands the entire category to one company, so it must be paired with performance obligations or the patent can simply be parked. Minimum annual royalties: a floor payable whether or not the licensee sells anything, which is the practical mechanism for preventing a product being shelved to protect an existing line. The royalty base: "net sales" is defined in the contract, not in the dictionary, and an unlimited deduction for returns, freight and promotional allowances can quietly halve the payment. Termination and reversion: the terms on which the rights come back if the licensee stops performing.
An agreement with a modest rate, a firm annual minimum and a clean reversion clause reliably outperforms a headline-grabbing rate with none of those protections. Most experienced practitioners of new product licensing reach the same conclusion from the other direction: the structure is what pays, not the percentage.
A five per cent royalty on a product nobody is contractually obliged to sell is worth precisely nothing.
Why minimums matter more than rates
Route Two
Manufacturing It Yourself
Producing and selling directly keeps the whole margin instead of a small slice of it, and keeps control of quality, pricing and brand. It also requires capital before revenue: tooling, a first production run, packaging, certification where the category demands it, warehousing, and the working capital to sit on stock while retail terms run their course.
The failure mode is rarely the product. It is the gap between paying for inventory and being paid for it. Retailers commonly settle sixty to ninety days after delivery, and a growing direct business can be profitable on paper and insolvent in the bank. The route suits inventors with existing commercial experience, a high-margin niche, or a product simple enough to make in small batches while demand is proven.
Route Three
Assignment: Selling the Patent Outright
An assignment transfers ownership for a fixed sum. It ends the relationship, ends the risk and ends the upside. It makes sense where the buyer has a specific strategic need, where the inventor has no appetite for a decade of royalty administration, or where the technology sits in a field the inventor has no intention of staying in.
The difficulty is valuation. A patent's worth depends on a market that does not exist yet, and buyers price that uncertainty into the offer. Sales before grant, or before any commercial validation, are almost always cheap in hindsight — which is the usual argument for licensing first and selling later, once revenue has established what the thing is actually worth.
The Approach
What a Company Wants to See
Companies evaluating an outside submission look at a narrow set of things: whether the product fits a line they already sell, whether the claimed protection is real and enforceable, whether it can be made at a cost that supports the category's margins, and whether the market is large enough to justify the tooling. Notably absent from that list is how ingenious the idea is.
The material that answers those questions is a working prototype or a convincing rendering, a one-page summary of the benefit in the buyer's own language, the filing status, and a realistic estimate of manufacturing cost. What should not be sent unprompted is a full technical disclosure without a filing in place, for the reasons set out in the earlier account of the stages between an idea and an application. Products spanning very different categories — from green technology to wearable pain-relief devices — converge on the same submission discipline, and profiles of long-running practitioners in the field, such as this account of decades spent working with independent inventors, describe the same short checklist over and over.
None of the three routes is inherently better. Licensing trades margin for reach, manufacturing trades capital for control, assignment trades upside for certainty. What is consistently a mistake is deferring the choice — because the answer determines what the prototype should cost, which claims are worth pursuing, and how much of the twenty-year term is spent deciding rather than selling. The persistent cultural interest in invention, examined in pieces on the fascination with innovation, tends to skip this part entirely. It is the part that decides the outcome.
End of report